VePesid®/Platinol® Remains Standard-of-care for Small Cell Lung Cancer
For patients diagnosed with extensive-stage small-cell lung cancer (SCLC), the standard-of-care remains the chemotherapy combination of VePesid® (etoposide) and Platinol® (cisplatin). A recent study indicates that Camptosar® (irinotecan) plus Platinol does not improve survival in SCLC compared with VePesid/Platinol. These findings were presented at the 2008 annual meeting of the American Society of Clinical Oncology.
This entry was posted on Saturday, June 7th, 2008 at 10:48 am and is filed under Research, Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.